Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia
Authors' conclusion
In this mathematical modelling analysis, evinacumab treatment could potentially increase long-term survival vs. standard-of-care LLTs for patients with HoFH.
Study context
- Population
- Modelled population of patients with homozygous familial hypercholesterolaemia (HoFH)
- Comparison
- Evinacumab added to standard-of-care Lipid-lowering Therapies (LLTs) vs standard-of-care LLTs
- Outcome
- Median survival (life expectancy)
Methodological detailsMarkov model
- Markov model
Main finding
As reported in the abstract
Median survival (Markov modelling)
Untreated
33-43
median survival · years
- High-intensity statin (HIS) increased median survival
- 9 years
- Ezetimibe further increased median survival
- an additional 9 years
- PCSK9i added on top of HIS plus ezetimibe further improved median survival
- 14 years
- Addition of evinacumab to standard-of-care LLTs estimated to increase median survival
- ∼12 years
Original publication
Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol. Published 14 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →